Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, D 60590 Frankfurt am Main, Germany.
Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001.
Topical calcineurin inhibitors have developed a bad connotation because of a black-box warning that was based on safety concerns of hypothetic systemic absorption and because systemic treatment with calcineurin inhibitors in patients who receive organ transplants is associated with an increased cancer risk. A few case reports of lymphoma and skin cancer in patients treated with topical calcineurin inhibitors initiated the discussion. These drugs were recommended for use as second-line therapy for the short-term and noncontinuous treatment of atopic dermatitis in patients who do not respond adequately to topical corticosteroids or in whom they are contraindicated. According to the latest knowledge, there is no scientific evidence of an increased risk for malignancy due to a topical treatment with calcineurin inhibitors.
由于基于潜在全身吸收的安全性担忧而发出的黑框警告，以及器官移植受者接受全身钙调磷酸酶抑制剂治疗与癌症风险增加相关，局部钙调磷酸酶抑制剂已产生不良联想。少数关于接受局部钙调磷酸酶抑制剂治疗的患者发生淋巴瘤和皮肤癌的病例报告引发了相关讨论。这些药物被推荐作为二线治疗药物，用于对局部皮质类固醇治疗反应不足或存在禁忌证的特应性皮炎患者进行短期非连续性治疗。根据最新知识，局部应用钙调磷酸酶抑制剂治疗不会增加恶性肿瘤的风险，目前尚无科学证据支持这一观点。
